| INTRODUC TI ON
The continuing disparity between demand and supply for kidney transplants has exerted pressure on the transplant community to utilize donors at increased risk of transmission of bloodborne infections such as hepatitis B, human immunodeficiency virus, and hepatitis C virus (HCV). HCV donor antibody (Ab) +/nucleic acid test (NAT) + positive donor (D+) kidneys are now increasingly being offered to HCV NAT+ recipients due to published data that HCV NAT+ kidney transplant recipients (positive recipients [R+] ) can significantly cut short their waiting time if they are willing to accept HCV D+ kidneys. 1, 2 The shorter waiting time can result in an overall improved mortality without any significant worsening of hepatitis C-relatedliver disease. 3 Unfortunately, a large proportion of D+ kidneys might never be used due to the unavailability of R+ candidates. Reese tality compared with matched controls on the waitlist who never received a transplant. 8 The generalizability of these findings was limited by the fact that HCV NAT testing was not available for a large majority of donors. Thus, it is conceivable that many donor kidneys could have been HCV Ab+/NAT−, resulting in a minimal infectious transmission risk.
The development of direct-acting antiviral (DAA) drugs for the treatment of hepatitis C has changed the landscape of HCV therapy with high rates of sustained virologic response (SVR) even for patients with kidney transplants. [9] [10] [11] [12] With these advances in therapy, there is a potential of preemptive treatment with DAAs allowing for safe transplantation of D+ kidneys into needy R− recipients to minimize any risk of viral transmission. Early data from some pilot studies suggest that this is feasible. 13, 14 While data on safety and efficacy are becoming available, the cost-effectiveness of such a strategy is less clear. Thus, it is necessary and important to assess the cost-effectiveness of this approach, given the fact that DAAs are extremely expensive.
To address this gap in knowledge, we performed a costeffectiveness analysis comparing 2 strategies: (a) renal transplantation (RT) from a HCV+ donor (D+) into HCV− recipients (R−) followed by immediate DAA therapy vs (b) HCV− recipients (R−) continuing dialysis and waiting for RT from a HCV− donor (D−).
| ME THODS
The Registry of Transplant Recipients (SRTR) 2016 Annual Report. 15 All data were the latest available records for a 2011 ESRD incident patient cohort followed for 5 years. The same data source was used for obtaining cumulative death probabilities of ESRD adult patients undergoing dialysis while waitlisted for RT. These data came from the latest available records of a 2013 ESRD incident patient cohort followed for 3 years, plus an estimation of another 2 years follow-up to fit our 5-year time frame. We used an exponential model to estimate the rates for the last 2 years for 2 reasons: (1) the literature indicates that the annual death rates increase over time for waitlisted dialysis patients 16 ; (2) the exponential model provides an average annual mortality rate of ≈5% over the 5-year frame. This is consistent with expert opinion and literature. 15 We then took the cumulative death probabilities and calculated corresponding annual death probabilities (see Supporting Information). 
100%
Additional acute rejection probability for transplant using a HCV+ kidney compared to that using a HCV− kidney remained on dialysis until a HCV-negative (D−) kidney became avail- were adjusted to 2017 US dollars, using the Consumer Price Index (CPI). 21, 22 Specifically, the medicinal drugs CPI was used to adjust immunosuppressive medication and dialysis-related medication costs.
The inpatient hospital service CPI was used to adjust the RT DRG cost, while the physician's services CPI was used to adjust costs of corresponding provider services related to RT. The medical care services by other medical professionals CPI were used to adjust dialysis cost. Indirect and intangible costs were not modeled.
A number of assumptions were made in developing the model:
1. HCV− and HCV+ transplant patients received the same surgical procedure and the same posttransplant care (ie, hospitalization, follow-up monitoring, and follow-up blood tests).
The immunosuppressive therapy is the same for patients receiv-
ing HCV− and HCV+ kidneys.
3.
To fit a parsimonious model, graft failures and other complications or adverse events (eg, infections or malignancies) associated with immunosuppressive therapy were not modeled. We made a conservative assumption that the D+/R− group would have a higher acute rejection rate than the D−/R− group. To simplify the model, rather than modeling the acute rejection rate for each group, we modeled the difference in acute rejection rates between the groups. We modeled this as a 10% acute rejection rate in the D+/ R− group and a 0% acute rejection rate in the D−/R− group.
4.
All D+/R− patients were infected with HCV (NAT+) and received DAA treatment.
5.
DAA consisted of 12 weeks of therapy with grazoprevir/elbasvir 50/100 mg (Zepatier; Merck, NJ), 1 tablet daily for 12 weeks.
DAA treatment resulted in HCV cures for 94% of D+/R− patients. This assumption is supported by previous studies using DAA to treat HCV after RT. [9] [10] [11] [12] [13] 23 The remaining 6% of patients received a second round of DAA therapy. After the second round of DAA therapy, 89% of patients were cured based upon recent studies in the general population with or without kidney disease. [24] [25] [26] We used a conservative estimate of the lowest SVR12 (89%) published for patients with a primary treatment failure as our base case. The remaining 11% of patients were assumed to have similar clinical outcomes over the 5-year time frame of our study. Sensitivity analyses were conducted using a lower cure probability (75% for the initial round of therapy and 71% for the second round of therapy) and a 20% higher death probability (25%) for patients who failed the second round of DAA therapy. Additional sensitivity analyses were performed using other available DAAs on the market including sofusbuvir/ ledipasvir (Harvoni; Gilead, CA), sofosbuvir/velpatasvir (Epclusa; Gilead, CA), sofosbuvir/velpatasvir/voxilaprevir (Vosevi; Gilead, CA), and glecaprevir/pibrentasvir (Mavyret;
Abbvie, IL). The upper end of our sensitivity analysis range was the highest National Average Drug Acquisition Cost price of these 5 DAA therapies in the current market. The lower end of our sensitivity analysis range was the least expensive 340B
price of the same 5 DAA therapies at our health system.
6.
Cumulative death probabilities after RT were the same for D+/ R− and D−/R− patients. We did additional sensitivity analysis assuming a 20% higher probability of death in D+/R− patients compared to D−/R− patients.
7. D+/R− patients received a transplant within the first 3 months of the study's 5-year time frame. Sensitivity analysis was performed assuming waiting times from 0 to 24 months.
8.
Patients waiting for an HCV+ kidney did not die within the first 3 months of the 5-year time frame.
9.
For patients remaining on dialysis, the probabilities of getting a HCV− kidney were 0% during year (Y)1, 25% by the end of Y2, 50% by the end of Y3, 75% by the end of Y4%, and 100% by the end of Y5. Sensitivity analysis was conducted assuming the probabilities of getting an HCV− kidney were 25% by the end of Y1, 50% by the end of Y2, 75% at the end by Y3%, and 100% by the end of Y4.
10.
Patients who died during a given year were assumed to have died at the end of the year (rather than at some other time within that year).
11.
The outcomes of patients remaining on dialysis were evaluated at the end of years 2, 3, and 4, as the probability of getting a D− kidney increased each year. Year 1 outcomes were built into the year 2 assessment, because we assumed there is 0% probability of getting a HCV− kidney at the end of year 1. Year 5 outcomes were excluded to avoid inflated costs because we assumed there was a 100% probability of getting a HCV− kidney by the end of 
12.
Mortality probabilities for the study patient cohort were same as for the patient cohort included in the 2016 OPTN/SRTR Annual Report. Additional sensitivity analyses were performed using both higher and lower mortality rates for both posttransplant and waitlisted dialysis patients.
| RE SULTS
The decision tree is shown in Figure 1 . with DAA and published 5-year survival rates (87%), the cost of the D+/ R− strategy was ≈$138 000. In comparison, for those who remained on dialysis while waiting for a HCV-negative organ, the costs and YOL ranged from $143 594 and 1.5 years, respectively, in those who died within 2 years while on dialysis to $478 645 and 5 YOL, respectively, for those who were still waiting for an organ on dialysis after 5 years.
Because of the cost of dialysis, the shorter the wait time for a HCV-neg- As shown in Table 3 , the D+/R− strategy remained dominant in all 1-way sensitivity analyses including adjustment for RT cumulative death probability (D+/R− was equivalent to or 20% higher than D−/ R−), difference in acute rejection probability between strategies (D+/ R− was 5%-20% higher than D−/R−), DAA therapy cure rate (75%-94%
for the first round; 71%-89% for the second round), death probability after the second round of DAA therapy failure (failure group was equivalent to or 20% higher than the success group), waiting time on 
| D ISCUSS I ON
The advent of DAA therapy has created a new paradigm for the therapy of hepatitis C. In addition to providing a cure for a large majority of patients infected with HCV, these drugs have opened a pathway for the use of HCV viremic donor organs into HCVnegative recipients followed by DAA therapy to eliminate the risk of donor-derived HCV disease. Early pilot studies suggest that this is clinically feasible and excellent sustained virologic responses can be achieved both for kidney as well as other solid-organ transplants. In addition, it was reported that between 29% and 82% of the potential HCV− kidney transplant recipients on the waiting list might be willing to accept HCV+ kidneys under certain scenarios. 27 In an analysis using contemporaneous cost data from Medicare (in US dollars), we now report that in addition to providing extra years of life for patients, this technique results in lower costs.
When compared to staying on dialysis and waiting for an HCV-negative donor kidney, the baseline cost-effectiveness analysis found that the D+/R− strategy resulted in an average of about one tenth of an additional year of life with a cost-saving of approximately $190 000 per patient. The D+/R− strategy remained dominant even after sensitivity analyses (Table 3) for a variety of variables. It should be noted that the use of yearly waitlist mortality in our study (done using only a 5-year time frame) does not capture the long-term benefits of transplantation extending beyond 5 years. In addition, it also does not capture the mortality of patients who were never waitlisted (or removed from the waitlist after waiting a few years) because they were considered too sick for transplantation. Thus, we believe that in the long-term the HCV D+/R− strategy might result in additional YOL than suggested by our results.
As expected, the difference between total calculated costs of the D+/R− strategy and that of the D−/R− strategy decreased as the cost of RT or DAA therapy increased. Since an important focus of the D+/R− strategy is the cost of DAA therapy, we took a very conservative approach in our sensitivity analysis. Even an increase in the cost of DAA therapy by 50% did not change the dominance of the D+/R− strategy. Our results indicate that, all other factors being equal, the cost of RT would have to be about a million USD or the cost of DAA therapy about $235 000 USD to make the expected costs of the D+/R− and D−/R− strategies equal. In fact in the actual market, it is currently apparent that the new DAA therapy combinations are less costly than the older ones and even the older ones have higher rebates than available previously.
The findings in our study corroborate that of the previous expert opinions as well as the data published from the United Kingdom recently. 28 There are limitations to this analysis, as we used several assumptions for the derivation of our cost-effectiveness models. We assumed that survival probabilities after RT were the same for D+/ R− and D−/R− patients. While there is scant clinical evidence to support or refute this assumption, we did do an additional sensitivity analysis assuming a 20% higher probability of cumulative death in D+/R− patients compared to D−/R− patients. This did not change our results significantly (Table 3 ). In addition, the 2 recently reported HCV D+/R− pilot trials did not report an increase in acute rejection, increased infections, early graft loss, or patient mortality in recipients of HCV D+/R− kidneys, thus supporting our assumption. 13, 14 In fact, since HCV+ donors are much more likely to be younger, it is also possible that long-term graft survival might be better for this population than estimated. 1, 4 It should also be noted that our data were limited to patients insured by Medicare, and thus findings may not be generalizable to patients with private health insurance. However, there is no reason to believe that these data would not be applicable to those with non-Medicare coverage.
Our analyses only included costs directly related to the transplant or to dialysis. That is, we did not include other health care costs-such as the cost of managing hypertension, diabetes, bone disease, anemia, access complications, etc-incurred by patients on dialysis or after transplant. If such costs were substantially higher for transplant patients than for dialysis patients, then our cost-savings might be overestimates. However, our sensitivity analyses indicate that these differences would have to be very large-around $190 000 per patient in most cases-to eliminate the cost-savings of the D+/R− strategy.
For the purpose of this analysis, we conservatively assumed that all patients would get HCV infection. Infection transmission has ranged anywhere from 0% to 100% based upon the previous data accumulated over the last 3 decades. 5, 7, 31 Thus, it is possible that some patients can avoid HCV transmission and might not require DAA therapy. This could potentially result in additional cost-savings. We also assumed that DAA treatment would result in cures for 94% of patients. This assumption is supported by previous studies using DAA to treat HCV after RT. 8, 9, 16 Further sensitivity analyses using a lower cure probability and a higher death probability for patients who failed the second round of DAA therapy did not alter the results significantly (Table 3) .
Finally, we assumed that 100% of HCV D+/R− patients will receive a kidney transplant between 3 and 24 months from listing.
Although these data are corroborated by previous evidence as well as our own ongoing study on HCV D+/R− kidney transplants (# NCT03249194), it might not be true for some parts of the The upper end of our sensitivity analysis range is the highest NADAC price of the 5 most commonly used DAA therapies in the current market: Zepatier, Mavyret, Vosevi, Harvoni, and Epclusa. The lower end of our sensitivity analysis range is the least expensive 340B price of the same 5 DAA therapies at our health system. TA B L E 3 (Continued) country. 1 On the other hand, we did use a conservative assumption that all HCV D−/R− patients will receive a kidney transplant by the end of the fifth year on the waiting list. Since wait times can be much longer in many parts of the country, this could have resulted in an underestimation of the cost-effectiveness of the HCV D+/R− approach. Finally, this is a population-based study in which we looked at averages across the dialysis population rather than at specific patient subtypes. It was not our intention to provide estimates for specific patient types, nor do we have the data to support this.
In conclusion, our analysis performed using a third-party payer's perspective suggests that utilization of HCV donor-positive kidney transplants for HCV-negative recipients is cost-effective. This strategy provides for equal or slightly reduced mortality and substantially reduced costs by limiting dialysis time.
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